



Sopida Pimcharoen

Ph.D. Student in Bioengineering, admitted Autumn 2023

Publications

PUBLICATIONS

- **Human cathelicidin peptide LL-37 compacts nucleic acids and alters neutrophil extracellular trap structure.** *Scientific reports*
Zielke, C., Rad, B., Nielsen, J. E., Li, J., Pimcharoen, S., Sawant, M., Kamayirese, S., Lin, J. S., Thiam, H. R., Barron, A. E.
2026
- **A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma** *MOLECULAR THERAPY ONCOLOGY*
Stauber, D., Sosnick, L., Ma, Y., Pimcharoen, S., Lawanprasert, A., Murthy, N., Myung, D., Qi, L. S.
2026; 34 (1)
- **A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma.** *Molecular therapy. Oncology*
Stauber, D., Sosnick, L., Ma, Y., Pimcharoen, S., Lawanprasert, A., Murthy, N., Myung, D., Qi, L. S.
2026; 34 (1): 201151
- **Investigation of Regulation and Binding Patterns of the Human Cathelicidin Peptide LL-37 in Complexation with Nucleic Acids, and its Impact on Neutrophil Extracellular Traps.** *bioRxiv : the preprint server for biology*
Zielke, C., Rad, B., Nielsen, J. E., Li, J., Pimcharoen, S., Sawant, M., Lin, J. S., Thiam, H. R., Barron, A. E.
2026
- **CRISPR activation of the ribosome-associated quality control factor ASCC3 ameliorates fragile X syndrome phenotypes in mice.** *Science translational medicine*
Geng, J., Wang, X., Pan, J., Khan, D., Pimcharoen, S., Zhang, Y., Mosammaparast, N., Hirose, S., Petrucelli, L., Brandman, O., Qi, L. S., Lu, B.
2025; 17 (819): eadq3551
- **CRISPR-Cas13d-Mediated Targeting of a Context-Specific Essential Gene Enables Selective Elimination of Uveal Melanoma.** *bioRxiv : the preprint server for biology*
Stauber, D., Sosnick, L., Ma, Y., Pimcharoen, S., Lawanprasert, A., Murthy, N., Myung, D., Qi, L. S.
2025
- **Acid-degradable lipid nanoparticles enhance the delivery of mRNA.** *Nature nanotechnology*
Zhao, S., Gao, K., Han, H., Stenzel, M., Yin, B., Song, H., Lawanprasert, A., Nielsen, J. E., Sharma, R., Arogundade, O. H., Pimcharoen, S., Chen, Y. J., Paul, et al
2024